27th February 2025

A 48-year-old postmenopausal woman started denosumab one year ago after a post-DXA scan FRAX score was found to be above the interventional threshold, and she felt oral bisphosphonates required too much effort for her to adhere to treatment.

A 48-year-old postmenopausal woman started denosumab one year ago after a post-DXA scan FRAX score was found to be above the interventional threshold, and she felt oral bisphosphonates required too much effort for her to adhere to treatment. She complains of tingling around her lips and recurrent muscle cramps, and blood tests demonstrate hypocalcaemia and vitamin D deficiency, so denosumab is discontinued.

What should further management involve?

Select the SINGLE most appropriate option from the list below. Select ONE option only.